Inclusion Criteria:  Age ≥ 18 years; Participant must be naïve to aspirin, defined as absence of chronic treatment with aspirin within the previous 3 months, and of any aspirin use within the previous 2 weeks;  Type 2 diabetes, based on at least one of the following criteria: (5)  Chronic treatment with oral antihyperglycemic agents or insulin therapy; Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (7.0 mmol/L) (fasting is defined as no caloric intake for at least 8h); 2-h Plasma Glucose (2h-PG) ≥200 mg/dL (11.1 mmol/L) during the oral glucose tolerance test (OGTT); A1C ≥ 6.5% (48 mmol/mol); Willing to attend all study visits.  Exclusion Criteria:  Definitive indication for aspirin, including any evidence of atherosclerotic disease, previous or current; Known hypersensitivity to aspirin; High-risk GI bleeding features, such as known H. pylori infection, past or present ulcer, history of bleeding from the GI tract; Bleeding diathesis; History of hematological malignancy or myelodysplasia; Platelet count or hemoglobin levels outside of the normal reference range; Planned major surgical procedure within 30 days of enrolment; Chronic inflammatory disease requiring regular anti-inflammatory treatment; Chronic treatment with an oral anticoagulant, an antiplatelet agent, NSAIDs or systemic steroids; Active cancer; Pregnant or lactating women.